An Extension Study Evaluating the Long-Term Safety and Tolerability of Degarelix One-Month Depots in Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring Prostate Cancer, Androgen ablation therapy
Eligibility Criteria
Inclusion criteria: Had given written consent before any study-related activity was performed (a study-related activity was defined as any procedure that would not have been performed during the normal management of the participant) Had completed the FE200486 CS12 study Exclusion criterion: Had been withdrawn from the FE200486 CS12 study
Sites / Locations
- UCL Saint Luc
- UZ Gent
- UZ Gasthuisberg, Urology Department
- Vivantes Klinikum am Urban, Klinik für Urologie
- Urologische Universitätsklinikum, Klinikum Mannheim GmbH, Fakultät für Klinische Medizin Mannheim
- Bajcsy-Zsilinszky Hospital, of local Government of Budapest, Dept. of Urology
- Jahn Ferenc Dél-Pesti Hospital, Dept. of Urology
- Pez Aladar County Hospital, Dept. of Urology
- Bács-Kiskun County Hospital, Dept. of Urology
- BAZ County Hospital, Dept of Urology
- Hospital of Local Government of Szeged, Dept. of Urology
- MÁV Hospital, Dept. of Urology
- Academic Medical Center, Dept. of Urology
- Atrium MC, Dept. of Urology
- "Prof.Dr.Th.Burghele" Hospital - Bucharest
- "Sf. Ioan" Emergency Hospital - Urology Department
- CF2 Hospital - Bucharest, Urology Department
- Fundeni Clinical Institute - Bucharest, Urology Department
- Moscow State University of Medicine and Dentistry, Department of Urology, Urogynecology and Andrology, City Hospital #50, Urology Department
- Russian Medical Academy of Postgraduate Education, Department of Gerontolology and Geriatrics, Moscow City Hospital #60, Urology Department, 84/1, Entuziastov Shosse (Hospital)
- Russian Medical Academy of Postgraduate Education, Urology Department, Moscow Clinical Hospital n.a. Botkin, Urology Department, 5/16, 2-oy Botkinsky proezd (Hospital)
- Russian State Medical University, Department of Urology and Surgical Nephrology, Moscow City Hospital #1
- City Hospital #15, Urology Department
- City Hospital #26, Urology Department
- I.I. Mechnikov St. Petersburg State Medical Academy, Urology Department
- Research Institute of Urology of the Ministry of Healthcare of the Russian Federation
- St. Petersburg Pavlov Medical School, Urology Department
- St.Petersburg Pavlov Medical School, Outpatient Diagnostic Center
- "Andros" Urology Clinic, 36A, Lenina St.
- Glenwood Hospital
- WITS Medical School, Level 9
- 401 B Medical Centre
- Pretoria Urology Hospital, Suite 2, Hatfield
- Sunninghill Clinic, Suite 3
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Degarelix 80 mg
Degarelix 120 mg
Degarelix 160 mg
Participants who completed the CS12 study in the Degarelix 80 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
Participants who completed the CS12 study in the Degarelix 120 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).
Participants who completed the CS12 study in the Degarelix 160 mg arm continued that dose into the CS12A extension study. After a protocol amendment in January 2006 all study participants were treated with 160 mg (40 mg/mL).